Search
GPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitIt is marketed in Canada by Valeant under the tradename Cophylac.
Nifedipine
go.drugbank.com/drugs/DB01115ApprovedInvestigationalNifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine]. … [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.
Products: NIFEDIPINO MK 10 MG. CAPSULASPlicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnIt appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste.
Medical air
go.drugbank.com/drugs/DB09337ApprovedInvestigationalVet approvedMedical air is supplied by a special air compressor to patient care areas using clean outside air.
Hyaluronidase (ovine)
go.drugbank.com/drugs/DB00070ApprovedHighly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalby the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigationalRecurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory … [L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]